Abbott acquires Kalila Medical, expands heart rhythm disorder portfolio

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Abbott announced on Feb. 2 that it acquired Kalila Medical, a privately held company that develops medical devices to treat atrial fibrillation and other heart rhythm disorders. Terms of the deal were not disclosed.

In 2014, the FDA granted Kalila Medical 510(k) clearance for its steerable introducer sheath that helps physicians access and perform catheter-based electrophysiology procedures.

Abbott has recently been expanding its atrial fibrillation business, including the 2014  acquisition of Topera, a company that develops electrophysiology technologies to diagnose and treat patients with atrial fibrillation. In January 2016, Abbott released a software update to provide enhanced rotor visualization for serious heart rhythm disorders.